Effectiveness of Antidiabetic Treatment Applied in Childhood Obesity

In our study, there are 33 healthy children with normal weight (control group) and 52 obese children who will be treated with metformin. To observe the efficacy of the 3-month treatment before and after metformin treatment, Zn, Zinc α-2 Glycoprotein (ZAG), Peroxisome proliferation activating receptor γ (PPARγ), Leptin (LEP) and Adiponectin (ADIPO) levels were compared, as well as anthropometric measurements and routine biochemistry tests.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Childhood Obesity Body Weight Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Pediatric Obesity Signs and Symptoms

Age range

9 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Erciyes University

Kayseri, Melikgazi, 38030, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Body mass index (BMI) > 95th percentile
Having insulin resistance
Having a family history of Type 2 diabetes mellitus (T2DM)

Exclusion criteria

;

Alcohol consumption and smoking
Having T1DM and T2DM
History of drug use

Treatment and study plan

metformin

Drug

Only obese children with insulin resistance were treated with metformin.

Primary outcomes

Insulin resistance (HOMA-IR) level

Time frame: three months

HOMA-IR is a condition in which the body's cells become less responsive to the effects of insulin. This means that the body needs more insulin to achieve the same effects, such as regulating blood sugar levels
Weight loss rate

Time frame: three months

Weight loss rate is typically defined as the amount of weight lost over a specific period of time.

Sponsors and collaborators

Lead sponsor

HÜMEYRA ACIKAN

Other

Registry information

Official study title

The Effect of Anti-diabetic Treatment Applied in Childhood Obesity on Zinc, Zinc α-2 Glycoprotein and Peroxisome Proliferation Activating Receptor-γ Levels

Important dates

Study start: 2019
Primary completion: 2021
Study completion: 2021
First posted: Feb 20, 2024
Registry last updated: Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed